The hottest Antitrust enforcement Substack posts right now

Biden's administration is taking steps to reduce corporate power through measures like capping credit card late fees and focusing on monopolies in the healthcare sector.
There is a mix of positive and negative actions within the Biden administration towards tackling concentrated economic power, showcasing a nuanced approach to corporate regulation.
Despite Biden's populist State of the Union rhetoric, the administration faces challenges in fully addressing corporate power and governance issues, including instances of corruption and policy setbacks.

Capital One is trying to purchase Discover for $35 billion due to a loophole the Federal Reserve left in banking laws, which allows Capital One to have control over pricing in ways its competitors cannot.
The credit card system in the U.S. involves a complex web of fees and intermediaries that result in high costs for merchants, driving the merger between Capital One and Discover in a pursuit for more pricing power.
The merger faces opposition from various groups due to concerns about increased monopolization and reduced competition in the credit card industry, highlighting the need for reforms to promote fair commerce and innovation.

The pharmaceutical industry is heavily influenced by aggressive marketing campaigns targeted at doctors, controlled by corporations like IQVIA.
IQVIA, a major player in the healthcare industry, is involved in a trial over a merger that could impact the future of advertising to healthcare professionals.
The FTC alleges that IQVIA's acquisition of advertising firms like DeepIntent could lead to a monopolization of the healthcare provider advertising platform market.

The U.S. economy is performing well with job growth and low inflation.
Corporate pricing power is keeping prices high for consumers by limiting competition.
To address economic challenges, there's a need for vigorous antitrust enforcement to break up big corporations and prevent price gouging.

FTC Chair Lina Khan is actively fighting against predatory finance in health care, specifically targeting a private equity firm for monopolization in the anesthesiology industry.
The excessive prices in the American health care system are attributed to massive consolidation in various sectors, including the involvement of private equity firms focused on profit extraction.
The FTC's lawsuit against USAP and Welsh Carson highlights illegal practices in monopolization, price-fixing, and market allocation that have cost Texans millions, shedding light on the need to address predatory actions in the industry.

Get a weekly roundup of the best Substack posts, by hacker news affinity: